Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
588.71B
Market cap588.71B
Price-Earnings ratio
22.13
Price-Earnings ratio22.13
Dividend yield
2.13%
Dividend yield2.13%
Average volume
8.14M
Average volume8.14M
High today
$247.20
High today$247.20
Low today
$243.51
Low today$243.51
Open price
$244.81
Open price$244.81
Volume
2.37M
Volume2.37M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

With a market cap of 588.71B, Johnson & Johnson(JNJ) trades at $244.29. The stock has a price-to-earnings ratio of 22.13 and currently yields dividends of 2.1%.

On 2026-04-02, Johnson & Johnson(JNJ) stock traded between a low of $243.51 and a high of $247.20. Shares are currently priced at $244.29, which is +0.3% above the low and -1.2% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 2.37M, against a daily average of 8.14M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $141.50.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $141.50.

JNJ News

24/7 Wall St. 5h
The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income By Lee Jackson Published Apr 2, 8:10AM EDT Quick Read The Dividend Aristocr...

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income
The Motley Fool 7h
This Healthcare Stock Barely Flinches During Market Sell-Offs

Johnson & Johnson (JNJ 0.09%), since its 2023 spinoff of its consumer health division into Kenvue (KVUE +0.81%), no longer sells bandages. However, if you're lo...

This Healthcare Stock Barely Flinches During Market Sell-Offs
The Motley Fool 8h
Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm

Searches for the phrase "stagflation 2026" have skyrocketed more than 650% over the last three months, according to Google Trends. It's easy to understand why....

Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm

Analyst ratings

59%

of 29 ratings
Buy
58.6%
Hold
34.5%
Sell
6.9%

More JNJ News

The Motley Fool 1d
Legend Biotech Q2 2025 Earnings Transcript

Image source: The Motley Fool. Monday, Aug. 11, 2025 at 8 a.m. ET Call participants Chief Executive Officer — Ying Huang President of CARVYKTI — Alan S. Bash...

Legend Biotech Q2 2025 Earnings Transcript
Nasdaq 1d
JNJ Crosses Above Average Analyst Target

In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $180.54, changing hands for $181.62...

JNJ Crosses Above Average Analyst Target
Nasdaq 1d
Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation.

Key Points Johnson & Johnson has a stronger credit rating than the U.S. government. PepsiCo's brand loyalty gives it considerable pricing power. Walmart rank...

Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation.
Simply Wall St 1d
Johnson & Johnson Taps Royalty Pharma To Support Immunology Growth Plans

Johnson & Johnson (NYSE:JNJ) has entered a US$500 million R&D co-funding agreement with Royalty Pharma. The partnership is focused on advancing JNJ-4804, a fir...

Johnson & Johnson Taps Royalty Pharma To Support Immunology Growth Plans
Nasdaq 2d
The Dividend King That's Raised Its Payout for 63 Consecutive Years

Key Points Johnson & Johnson is a Dividend King. The company's strong operations suggest regular payout increases aren't a thing of the past. 10 stocks we li...

The Dividend King That's Raised Its Payout for 63 Consecutive Years
Investor's Business Daily 2d
Why Johnson & Johnson Is Rebounding — Finally

IBD Stock Of The Day Why Johnson & Johnson Is Rebounding — Finally Licensing Johnson & Johnson Johnson & Johnson JNJ $ 243.60 $1.11 0.46% 32% IBD Stock Analysis...

Why Johnson & Johnson Is Rebounding — Finally
24/7 Wall St. 2d
Here's Why You Don't Bet Against This Dividend King

Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has...

Here's Why You Don't Bet Against This Dividend King

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.